These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6142465)

  • 21. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.
    Azad Khan AK; Howes DT; Piris J; Truelove SC
    Gut; 1980 Mar; 21(3):232-40. PubMed ID: 6105118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation.
    Esbjörner E; Järnerot G; Wranne L
    Acta Paediatr Scand; 1987 Jan; 76(1):137-42. PubMed ID: 2882643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.
    Palmer KR; Goepel JR; Holdsworth CD
    Br Med J (Clin Res Ed); 1981 May; 282(6276):1571-3. PubMed ID: 6113021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis.
    Xu J; Tam M; Samaei S; Lerouge S; Barralet J; Stevenson MM; Cerruti M
    Acta Biomater; 2017 Jan; 48():247-257. PubMed ID: 27769943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
    Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
    Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
    d'Albasio G; Pacini F; Camarri E; Messori A; Trallori G; Bonanomi AG; Bardazzi G; Milla M; Ferrero S; Biagini M; Quaranta S; Amorosi A
    Am J Gastroenterol; 1997 Jul; 92(7):1143-7. PubMed ID: 9219787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulfasalazine-induced exacerbation of ulcerative colitis.
    Schwartz AG; Targan SR; Saxon A; Weinstein WM
    N Engl J Med; 1982 Feb; 306(7):409-12. PubMed ID: 6120459
    [No Abstract]   [Full Text] [Related]  

  • 34. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 35. [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].
    Guastavino E; Litwin NH; Heffes Nahmod L; Licastro R
    Acta Gastroenterol Latinoam; 1988; 18(2):107-13. PubMed ID: 2908013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chloroquine for mild to moderately active ulcerative colitis: comparison with sulfasalazine.
    Goenka MK; Kochhar R; Tandia B; Mehta SK
    Am J Gastroenterol; 1996 May; 91(5):917-21. PubMed ID: 8633581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.
    Bianchi Porro G; Ardizzone S; Petrillo M; Fasoli A; Molteni P; Imbesi V
    Am J Gastroenterol; 1995 May; 90(5):736-9. PubMed ID: 7733079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemolysis during salicylazosulfapyridine therapy.
    van Hees PA; van Elferen LW; van Rossum JM; van Tongeren JH
    Am J Gastroenterol; 1978 Nov; 70(5):501-5. PubMed ID: 33552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.
    Schröder H; Evans DA
    Gut; 1972 Apr; 13(4):278-84. PubMed ID: 4402420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.